Drugs & Targets FDA approves Lynparza with abiraterone, prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer June 02, 2023Vol.49 No.22
Drugs & Targets FDA approves Posluma—first radiohybrid PSMA-targeted PET imaging agent for prostate cancer June 02, 2023Vol.49 No.22
Clinical Roundup UC Davis study shows link between bone biomarkers and prostate cancer survival May 12, 2023Vol.49 No.19
Regulatory News ODAC says prostate cancer patients who lack proven BRCA mutation shouldn’t get PARP inhibitor May 05, 2023Vol.49 No.18By Paul Goldberg
Drugs & Targets FDA grants Fast Track designation for ¹⁷⁷Lu-PNT2002 for metastatic castration-resistant prostate cancer April 28, 2023Vol.49 No.17
Clinical Roundup Vitamin D may play a role in prostate cancer disparities, Cedars-Sinai researchers find April 21, 2023Vol.49 No.16
Clinical Roundup Study finds more U.S. prostate cancer patients choosing active surveillance April 07, 2023Vol.49 No.14
Clinical Roundup Phase II study shows novel immunotherapy is safe in prostate cancer April 07, 2023Vol.49 No.14
Clinical Roundup Metastasis-directed radiation therapy + hormone therapy improves PFS for advanced prostate cancer April 07, 2023Vol.49 No.14
Funding Opportunities DoD Prostate Cancer Research Program anticipated funding opportunities for FY23 March 10, 2023Vol.49 No.10
